

PCT

Express Mailing Label No.: EV 475171490 US  
Date of Deposit: June 23, 2005

Attorney Docket No. 23380-602 NATL



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Strittmatter et al.  
SERIAL NUMBER: 10/519,132 EXAMINER : Not Yet Assigned  
FILING OR 371(C) DATE: December 22, 2004 ART UNIT : Not Yet Assigned  
FOR: MODULATORS AND MODULATION OF THE INTERACTION  
BETWEEN RGM AND NEOGENIN

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages);
2. Modified Form 1449/PTO (3 pages), in duplicate;
3. Copies of Cited References: B1-12; C1-70; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23380-602 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529  
Gregory J. Sieczkiewicz, Reg. No. 48,223  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Date: June 23, 2005



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Strittmatter et al.  
SERIAL NUMBER: 10/519,132 EXAMINER : Not Yet Assigned  
FILING OR 371(C) DATE: December 22, 2004 ART UNIT : Not Yet Assigned  
FOR: MODULATORS AND MODULATION OF THE  
INTERACTION BETWEEN RGM AND NEOGENIN

**MAIL STOP AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A6 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Strittmatter et al.  
U.S.S.N.: 10/519,132

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23380-602 NATL.

Respectfully submitted,



Ivor R. Elfi, Reg. No. 39,529  
Gregory J. Sieczkiewicz, Reg. No. 48,223  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Date: June 23, 2005

TRA 2042468v1



Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO				Application Number		10/519,132	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Filing or 371(c) Date		December 22, 2004	
				First Named Inventor		Strittmatter	
				Group Art Unit		Not Yet Assigned	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		23380-602 NATL	
<b>U.S. PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	4,946,778	08/07/90	Ladner et al.	435	69.6	
	*A2	5,525,490	06/11/96	Erickson et al.	435	29	
	*A3	5,541,109	07/30/96	Searfoss III et al.	435	252.3	
	*A4	5,747,262	05/05/98	Hinck et al.	435	7.1	
	*A5	6,004,746	12/21/99	Brent et al.	435	6	
	*A6	6,087,326	07/11/00	Hinck et al.	514	2	
<b>U.S. PUBLISHED APPLICATION DOCUMENTS</b>							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	WO 94/29469	VICAL INCORPORATED; REGENTS OF THE UNIV. OF MICHIGAN	12/22/94			
	B2	WO 97/00957	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	01/09/97			
	B3	WO 98/25947	BRISTOL-MYERS SQUIBB COMPANY	06/18/98			
	B4	WO 99/51741	CURAGEN CORPORATION	10/14/99			
	B5	WO 00/02911	CURAGEN CORPORATION	01/20/00			
	B6	WO 00/05410	TECHNION RES. AND DEV. FOUNDATION LTD.	02/03/00			
	B7	WO 00/14271	LOMA LINDA UNIVERSITY	03/16/00			
	B8	WO 00/17221	DUKE UNIVERSITY	03/30/00			
	B9	WO 02/051438 A2	MAXPLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.	07/04/02			
	B10	EP 0 291 533	UNIVERSITY PATENTS, INC.	10/18/95			
	B11	EP 0 321 201 A2	COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RES. ORG.	06/21/89			
	B12	EP 0 360 257 A2	THE BOARD OF REGENTS FOR NORTHERN ILLINOIS UNIV.	03/28/90			
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Accession Number BC23870 (02/24/04)					
	C2	Accession Number AK080819 (04/03/04)					

C3	Accession Number BC022603 (01/03/05)
C4	Accession Number BI818609 (10/04/01)
C5	Accession Number BI769500 (09/25/01)
C6	Anderson <i>Science</i> , 256:808-813 (1992)
C7	Bagnard et al. <i>Development</i> , 125:5043-5053 (1998)
C8	Blömer et al. <i>J. Virol.</i> , 71(9):6641-6649 (1997)
C9	Bonhoeffer et al. <i>Trends Neurosci.</i> , 7:378-381 (1984)
C10	Caroni et al. <i>Neuron</i> , 1:85-96 (1988)
C11	Caroni et al. <i>J. Cell Biol.</i> , 106:1281-1288 (1988)
C12	Charron et al. <i>J. Biol. Chem.</i> , 270(43):25739-25745 (1995)
C13	Chen et al. <i>Nature</i> , 403:434-439 (2000)
C14	Cheng et al. <i>Cell</i> , 79(1):157-168 (1994)
C15	Cox et al. <i>Neuron</i> , 4(1):31-37 (1990)
C16	David et al. <i>Science</i> , 214:931-933 (1981)
C17	Davis et al. <i>Science</i> , 266:816-819 (1994)
C18	Drescher et al. <i>Cell</i> , 82(3):359-370 (1995)
C19	Famulok et al. <i>Curr. Op. Chem. Biol.</i> , 2:320-327 (1998)
C20	Fazeli et al. <i>Nature</i> , 386:796-804 (1997)
C21	Feldheim et al. <i>Neuron</i> , 21(6):1303-1313 (1998)
C22	Feldheim et al. <i>Neuron</i> , 25(3):563-574 (2000)
C23	Flanagan et al. <i>Annu. Rev. Neurosci.</i> , 21:309-345 (1998)
C24	Fournier et al. <i>Nature</i> , 409:341-346 (2001)
C25	Geddes et al. <i>Nat. Med.</i> , 3(12):1402-1404 (1997)
C26	Geddes et al. <i>Front Neuroendocrinol.</i> , 20(4):296-316 (1999)
C27	Geisbrecht et al. <i>J. Biol. Chem.</i> , 278(35):32561-32568 (2003)
C28	GenBank NT_039474 (08/31/04)
C29	Genbank NM_008684 (02/28/05)
C30	Gierer <i>Development</i> , 101(3):479-489 (1987)
C31	Giordano et al. <i>Nat. Med.</i> , 2(5):534-539 (1996)
C32	Gold et al. <i>Annu. Rev. Biochem.</i> , 64:763-797 (1995)
C33	Goodman <i>Annu. Rev. Neurosci.</i> , 19:341-377 (1996)
C34	GrandPré et al. <i>Nature</i> , 403:439-444 (2000)
C35	Hong et al. <i>Cell</i> , 97(7):927-941 (1999)
C36	Isner et al. <i>Lancet</i> , 348:370-374 (1996)
C37	Kasus-Jacobi et al. <i>Oncogene</i> , 19(16):2052-2059 (2000)
C38	Keeling et al. <i>Oncogene</i> , 15(6):691-700 (1997)
C39	Kohler et al. <i>Nature</i> , 256:495-497 (1975)
C40	Kolodkin et al. <i>Cell</i> , 75(7):1389-1399 (1993)
C41	Meier et al. <i>J. Neuropathol. Exp. Neurol.</i> , 58(10):1099-1110 (1999)
C42	Mey et al. <i>J. Hirnforschung</i> , 33:673-702 (1992)
C43	Mimms et al. <i>Virol.</i> , 176(2):604-619 (1990)

BEST AVAILABLE COPY

Date of Deposit: June 23, 2005

Attorney Pocket No.: 23380-602 NATL

C44	Ming et al. <i>Neuron</i> , 19(6):1225-1235 (1997)
C45	Monnier et al. <i>Nature</i> , 419:392-395 (2002)
C46	Mühlhauser <i>Circ. Res.</i> , 77:1077-1086 (1995)
C47	Müller <i>Curr. Biol.</i> , 6(11):1497-1502 (1996)
C48	Müller <i>Annu. Rev. Neurosci.</i> , 22:351-388 (1999)
C49	Nielsen et al. <i>Science</i> , 254:1497-1500 (1991)
C50	Püschel et al. <i>Neuron</i> , 14(5):941-948 (1995)
C51	Raper et al. <i>Neuron</i> , 4(1):21-29 (1990)
C52	Routbort et al. <i>Neurosci.</i> , 94(3):755-765 (1999)
C53	Santoro et al. <i>Proc. Natl. Acad. Sci. USA</i> , 94:4262-4266 (1997)
C54	Schaper et al. <i>Circ. Res.</i> , 79:911-919 (1996)
C55	Schnell et al. <i>Nature</i> , 343:269-272 (1990)
C56	Serafini et al. <i>Cell</i> , 87(6):1001-1014 (1996)
C57	Sharp <i>Genes Dev.</i> , 13:139-141 (1999)
C58	Sperry <i>Proc. Natl. Acad. Sci. USA</i> , 50:703-710 (1963)
C59	Stahl et al. <i>Neuron</i> , 5(5):735-743 (1990)
C60	Steinecke et al. <i>Meth. Cell Biol.</i> , "Ribozymes", Chapter 33, Galbraith, eds. Academic Press, Inc. 50:449-460 (1995)
C61	Tessier-Lavigne et al. <i>Science</i> , 274:1123-1133 (1996)
C62	Verma et al. <i>Nature</i> , 389:239-242 (1997)
C63	Vielmetter et al. <i>Exp. Brain Res.</i> , 81(2):283-287 (1990)
C64	Vielmetter et al. <i>J. Cell Biol.</i> , 127(6):2009-2020 (1994)
C65	Walter et al. <i>Development</i> , 101(4):685-696 (1987)
C66	Walter et al. <i>Development</i> , 101:909-913 (1987)
C67	Walter et al. <i>J. Physiol.</i> , 84:104-110 (1990)
C68	Wang et al. <i>Nat. Med.</i> , 2(6):714-716 (1996)
C69	Wang et al. <i>J. Neurosci.</i> , 19(12):4938-4947 (1999)
C70	Yu et al. <i>Nat. Neurosci.</i> , 4(Suppl):1169-1176 (2001)

\* By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A6 are not submitted.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 1995617v1

BEST AVAILABLE COPY